Idenix
Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged
in the discovery and development of drugs for the treatment of human viral
and other infectious diseases, announced that three abstracts have
been accepted for presentation at the 43rd Annual Meeting of the European
Association for the Study of the Liver (EASL) to be held in Milan, Italy,
April 23 - 27, 2008. Full abstracts can now be viewed at the EASL website
at easl.ch.
David Standring, Ph.D., Executive Vice President, Biology at Idenix
Pharmaceuticals, will present "In Vitro Activity and Pharmacologic
Properties of Two Novel Series of HCV Protease Inhibitors" in an oral
presentation session at 6:15 p.m. CET on Thursday, April 24, 2008.
Dr. Standring will also present, "Potent Antiviral Activity of Second
Generation Nucleoside Inhibitors, IDX102 and IDX184, in HCV-Infected
Chimpanzees" in an oral presentation session at 5:30 p.m. CET on Friday,
April 25, 2008.
Erika Cretton-Scott, Ph.D., Director, Preclinical Pharmacology at
Idenix Pharmaceuticals, will present "In Vitro Antiviral Activity and
Pharmacology of IDX184, a Novel and Potent Inhibitor of HCV Replication" in
a poster session beginning on Thursday, April 24, 2008.
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge,
Massachusetts, is a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral and other infectious
diseases. Idenix's current focus is on the treatment of infections caused
by hepatitis C virus and human immunodeficiency virus (HIV). For further
information about Idenix, please refer to idenix.
Forward Looking Statements
This press release contains "forward-looking statements" within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward- looking statements can be identified by implied discussions with
respect to the company's clinical development programs in hepatitis C, or
any potential pipeline candidates for the treatment of hepatitis C. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause actual results to be materially different
from any future results, performance or achievements expressed or implied
by such statements. There can be no guarantees that the company will
advance any clinical product candidate or other component of its potential
pipeline to the clinic, to the regulatory process or to commercialization.
In particular, management's expectations could be affected by unexpected
regulatory actions or delays; uncertainties relating to, or unsuccessful
results of, pre-clinical studies and/or clinical trials, including
additional data relating to the ongoing pre- clinical studies and/or
clinical trials evaluating its product candidates; the company's ability to
obtain additional funding required to conduct its research, development and
commercialization activities; the company's dependence on its collaboration
with Novartis Pharma AG; changes in the company's business plan or
objectives; the ability of the company to attract and retain qualified
personnel; competition in general; and the company's ability to obtain,
maintain and enforce patent and other intellectual property protection for
its product candidates and its discoveries. These and other risks which may
impact management's expectations are described in greater detail under the
caption "Risk Factors" in the company's annual report on Form 10-K for the
year ended December 31, 2006 and the Quarterly Report on Form 10- Q for the
quarter ended September 30, 2007, each as filed with the Securities and
Exchange Commission (SEC) and other filings that the company makes with the
SEC.
All forward-looking statements reflect the company's expectations only
as of the date of this release and should not be relied upon as reflecting
the company's views, expectations or beliefs at any date subsequent to the
date of this release. Idenix anticipates that subsequent events and
developments may cause these views, expectations and beliefs to change.
However, while Idenix may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any obligation to do
so.
Idenix Pharmaceuticals, Inc.
idenix